Select a Region North America

Insights

Insights From Our Experts

Articles

Successful Early-Stage Out-Licensing Requirements

The attention on vaccines during the COVID-19 crisis highlighted the role of biotech companies and positive sentiment increased for the sector. In 2021, a record number of biotech (100+) companies went public and listed companies soared…

EVERSANA’s Value & Evidence Team’s Work Tops List of Most Read Articles in 2021 in Journal of Comparative Effectiveness Research

If you work in the field of Health Economics and Outcome Research (HEOR) in the life sciences industry, you know just how valuable the Journal of Comparative Effectiveness Research (JCER) is. The publication features peer-reviewed studies…

Social Determinants of Health – What Pharma Can Do!

The US Department of Health and Human Services defines Social Determinants of Health (SDoH) as conditions in the places where people live, learn, work, and play that affect a wide range of health risks and outcomes.1…

Case Study: Leveraging machine learning models in patient identification and behavior prediction for rare disease indications

When a mid-sized pharmaceutical company was challenged with trial and adoption of their immune thrombocytopenia (ITP) drug due to fierce competition and the lingering impact of COVID-19, they turned to the team of data and analytics…

Flipping the Script to Disrupt, Redefine and Accelerate the Patient Care Journey

During the COVID-19 pandemic, patients and providers began to recognize the considerable benefits of telehealth services. Patient demand and notable increases in access to care for many have compelled the industry to adopt telehealth as a…

Three Keys to Value for Unlocking the Promise of Cell Therapies

The cell therapy market continues to grow. Estimated at $101 billion in 2021, the global cell therapy market is projected to reach $247 billion by 2028, a CAGR of 13.64%.1  The revenue generation is being driven…

Macroeconomic Factors Impact Cash Flow for Pharma

Worldwide inflation, ongoing effects of the COVID-19 pandemic and other macroeconomic factors continue to negatively impact established brands at a time when pharma companies need their positive cash flow the most to continue funding R&D. Leading…

How to Ensure Speed and Efficiency When Launching in Canada

Today is an extraordinary time for medical innovation. The pharmaceutical industry is yielding protection against diseases, focusing more on rare and complex disease treatments, and the world is getting better health outcomes. Global life expectancy is…

Reimagining the Patient Care Ecosystem​

Improving Access, Removing Barriers and Speeding Up Time to Therapy Patient demand for telehealth and a flood of industry challenges are disrupting the traditional healthcare landscape. Lack of patient awareness, access to care and overburdened clinicians…

Customer Centric Approach to Medical Affairs Leveraging Digital Technology

As technology advances the needs of healthcare professionals (HCPs) and patients evolve. The onset of the COVID-19 pandemic accelerated digital adoption among these groups. Medical Affairs departments now require a digital strategy in addition to medical…